Evidence map›Paper›PMID 30393547›Full record

ReviewJournal of hip preservation surgery2018

The use of platelet-rich plasma in the treatment of greater trochanteric pain syndrome: a systematic literature review.

Mohammed Ali, Eshan Oderuth, Ismael Atchia, Ajay Malviya

Open access · diamondAbstract readReview
In one paragraph

Review in Journal of hip preservation surgery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
6.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it, 66 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Polynucleotides High Purification Technology (PN HPTJournal of clinical medicine · 2025
    Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Analgesic effects of low-dose radiotherapy in greater trochanteric pain syndrome: results in a clinical series of 155 patients with recurrent or refractory symptoms.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022
    Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Mohammed AliTrauma and Orthopedics, Northumbria Healthcare NHS foundation Trust, North Shields, UK.ORCID 0000-0003-0012-0451
Eshan OderuthChesterfield Royal Hospital, Chesterfield, UK.
Ismael AtchiaConsultant Rheumatologist, Northumbria Healthcare NHS foundation Trust, Northumberland, UK.
Ajay MalviyaTrauma and Orthopedics, Northumbria Healthcare NHS foundation Trust, North Shields, UK.
Northumbria Healthcare NHS Foundation Trust · GBChesterfield Royal Hospital · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This review aims to determine whether platelet-rich plasma (PRP) has any role in improving clinical outcomes in patients with symptomatic greater trochanteric pain syndrome (GTPS). A search of NICE healthcare database advanced search (HDAS) via Athens (PubMed, MEDLINE, CINAHL, EMBASE and AMED databases) was conducted from their year of inception to April 2018 with the keywords: 'greater trochanteric pain syndrome' or 'GTPS' or 'gluteus medius' or 'trochanteric bursitis' and 'platelet rich plasma' (PRP). A quality assessment was performed using the JADAD score for RCTs and MINORS for non-RCT studies. Five full-text articles were included for analysis consisting of three RCTs and two case series. We also identified four additional studies from published conference abstracts (one RCT and three case series). The mean age in 209 patients was 58.4 years (range 48-76.2 years). The majority of patients were females and the minimum duration of symptoms was three months. Diagnosis was made using ultrasound or MRI. Included studies used a variety of outcome measures. Improvement was observed during the first 3 months after injection. Significant improvement was also noted when patients were followed up till 12 months post treatment. PRP seems a viable alternative injectable option for GTPS refractory to conservative measures. The current literature has revealed that PRP is relatively safe and can be effective SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42017080662. LEVEL OF EVIDENCE: Level I, systematic review of Level I studies.

Identifiers

PMID30393547
PMCPMC6206702
OpenAlexW2889526926

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.